Blis Technologies Limited

Overview

Blis is an NZX-listed manufacturer of advanced probiotic strains that enable the delivery of probiotic solutions for specific health targets including throat health, halitosis (bad breath), immune support and teeth and gum health. Combining innovation with evidence-based research has enabled the company to develop a range of products containing two strains of probiotic bacteria - BLIS K12 TM and BLIS M18 TM. Both of these strains occur naturally in the oral cavity however, only around 2% of the population have these healthy bacteria at levels high enough to be effective.

BLIS products have received regulatory approvals for sale throughout New Zealand, Australia, Asia, Europe and the USA. Brand names include ThroatGuard PRO, DailyDefence, TravelProtect, HoneyBlis, FreshBreath and ToothGuard.

Blis probiotics have a significant body of evidence which is constantly growing as more clinical trials are completed. Blis probiotics have been included in more than 40 clinical trials to date.

The company's origins lie in research undertaken by Professor Emeritus John Tagg of the Microbiology Department at the University of Otago in New Zealand who found that Salivaricin B, a substance which acts as a natural antibiotic, controls streptococcal throat infections. Blis Technologies commenced business in August 2000 when it acquired the University's collection of several thousand bacteriocin-producing organisms. It listed on NZX in 2001.

Performance

The following information was extracted from BLIS Technologies Limited's Market Update, released on 20 August 2026:

Strong 1Q27 supports growth outlook

BLIS Technologies Limited (BLIS) delivered revenue of $5.1m, for the first quarter ended 30 June 2026 (1Q27), an increase of $1.5m, or up 42%, on the same period last year. 1Q27 EBITDA was a $1.1m profit compared to a $0.2m loss for 1Q26. The 1Q27 financial information is unaudited and in New Zealand dollars.

B2B revenue was up 67% on 1Q26 driven by ingredient growth in Asia Pacific, strong Probi royalties and private label sales into China, partially offset by weaker ingredient revenue in Europe. Total B2C revenue was up 4% on 1Q26.

“We have had an exceptional start to the year, with record revenue and EBITDA. Although the first quarter should not be annualised to a full year, we are comfortable with our current forecast of 10%-15% revenue growth for FY27.” said Scott Johnson, CEO.